Evidence map›Paper›PMID 40717203›Full record

ArticleBrain tumor pathology2025

Integrated analysis of MYC expression, 8q24.21 copy number, and recurrence patterns in astrocytoma, IDH-mutant.

Masanobu Kumon, Shunsuke Nakae, Shigeo Ohba, Masato Abe, Seiji Yamada, Hikaru Sasaki, Takema Kato, Hiroki Kurahashi, Yuichi Hirose

Abstract read
PubMed Publisher
In one paragraph

Article in Brain tumor pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. MYC as a key target for melanoma therapy.Frontiers in cell and developmental biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Masanobu KumonDepartment of Neurosurgery, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan.
Shunsuke NakaeDepartment of Neurosurgery, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan. snakae1977@gmail.com.ORCID http://orcid.org/0000-0002-9080-455X
Shigeo OhbaDepartment of Neurosurgery, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan.
Masato AbeDepartment of Pathology, School of Health Sciences, Fujita Health University, Toyoake, Japan.
Seiji YamadaDepartment of Division of Analytical Pathology, Oncology Innovation Center, Fujita Health University School of Medicine, Research Promotion Headquarters, Toyoake, Japan.
Hikaru SasakiDepartment of Neurosurgery, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Japan.
Takema KatoDivision of Molecular Genetics, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Japan.
Hiroki KurahashiDivision of Molecular Genetics, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Japan.
Yuichi HiroseDepartment of Neurosurgery, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Compared to oligodendrogliomas, astrocytomas may have a relatively higher frequency of intracranial remote recurrence, despite generally favorable prognoses. Previous studies identified 8q gain, particularly in the terminal region, as a poor prognostic factor. This study evaluated MYC expression and its relationship with copy number gain at 8q24.21, in relation to recurrence patterns in astrocytomas, with a particular focus on intracranial remote recurrence. A retrospective analysis was conducted on 27 patients treated between 2006 and 2019. MYC expression was assessed by immunohistochemistry (IHC), and copy number status by metaphase comparative genomic hybridization and next-generation sequencing. Recurrence patterns were categorized as local or remote.Among 43 specimens analyzed by IHC, MYC expression was observed in 72%, with higher positivity in recurrent (80%) than initial (61%) specimens, though the difference was not statistically significant (p = 0.30). Copy number analysis showed a significant increase in 8q24.21 copy number in specimens from cases with remote recurrence compared to those with local recurrence (p = 0.033). However, no significant correlation was found between MYC copy number and protein expression (p = 0.055). These findings suggest that MYC is frequently expressed in astrocytomas, but its expression does not significantly reflect 8q gain or recurrence pattern.

Indexed as

AstrocytomaBrain NeoplasmsChromosomes, Human, Pair 8Isocitrate DehydrogenaseNeoplasm Recurrence, LocalProto-Oncogene Proteins c-mycAdolescentAdultAgedComparative Genomic HybridizationDNA Copy Number VariationsFemaleGene DosageHumansImmunohistochemistryMaleIDH1 protein, humanIsocitrate DehydrogenaseMYC protein, humanProto-Oncogene Proteins c-myc8q gainAstrocytomaMYC

Identifiers

PMID40717203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.